GH Research Reports Strong Phase 2b Results for 5-MeO-DMT in Treatment-Resistant Depression Post published:February 3, 2025 Post category:Analysis/News/Pα+
2025’s Psychedelic Policy Surge: A State-by-State, Bill-by-Bill Analysis Post published:January 31, 2025 Post category:Analysis/News/Pα+
Psychedelic Drug Development Pipeline Updates (Q1’25) Post published:January 30, 2025 Post category:2024 Year in Review/Analysis/News/Pα+
Pα+ Psychedelic Bulletin #186: As Trump Takes Office, Impact on Psychedelics Field Remains Unclear; The Jurvetsons Discuss Psychedelics at DLD; GH Shares PoC Data Post published:January 24, 2025 Post category:Psychedelic Bulletin/Pα+
mpathic Co-Founder Danielle Schlosser on AI Oversight of Psychedelics Trials Post published:January 17, 2025 Post category:Interviews/Pα+
Patent Analysis: Lykos Suffers Blow from USPTO As All Patent Claims Stand Finally Rejected Post published:January 16, 2025 Post category:Psychedelic Patent Analysis/Pα+
Pα+ Psychedelic Bulletin #185: Joe Rogan on Ibogaine; Wisconsin Medicaid to Cover IV Ketamine for Depression; Inside the Plan to Make Lykos MAPS Again Post published:January 11, 2025 Post category:Psychedelic Bulletin/Pα+
Billionaire Investor Antonio Gracias Plots $100M Lykos Takeover with Doblin’s Backing Post published:January 10, 2025 Post category:Analysis/News/Pα+
From Fringe to Focus: APA’s American Journal of Psychiatry Publishes Special Issue on Psychedelics Post published:January 7, 2025 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #184: Federal Psychedelics Lobbying Jumps 90% in Q3’24, with MDMA-AT the Key Topic Post published:December 31, 2024 Post category:Psychedelic Bulletin/Pα+